Chambers HF (2006) General Principles of Antimicrobial Therapy. In: Brunton LL, Lazo J,
Parker K (eds) Goodman Gilman’s the pharmacological basis of therapeutics. McGraw-Hill,
USA, pp 1095–1111
Chiller TM, Barrett T, Angulo FJ (2004) CDC studies incorrectly summarized in ‘critical review’.
J Antimicrob Chemother 54:275–276
Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: A new paradigm for antimicro-
bial therapy. Nat Chem Biol 3:541–548
Clinical Laboratories Standards Institute (2007) Development of in vitro susceptibility testing
criteria and quality control parameters for veterinary antimicrobial agents; approved guideline,
3rd edn. CLSI, PA, USA
Collignon P (2004) Antibiotic growth promoters. J Antimicrob Chemother 54:272
Conway TB, Beck FM, Walters JD (2000) Gingival fluid ciprofloxacin levels at healthy and
inflamed human periodontal sites. J Periodontol 71:1448–1452
Craig WA, Dalhoff A (1998) Pharmacodynamics of fluoroquinolones in experimental animals. In:
Born GVR, Cuatrecas P, Ganten D, Herken H, Melmon KL, Starke K (eds) Handbook of
experimental pharmacology. Springer, Berlin, pp 208–232
Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P (2004) In vivo
pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimen-
tal model of pneumonia: Impact of the low levels of fluoroquinolone resistance on the
enrichment of resistant mutants. J Antimicrob Chemother 54:640–647
Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3:
359–371
Davies J (1994) Inactivation of antibiotics and the dissemination of resistance genes. Science
264:375–382
Davison HC, Low JC, Woolhouse MEJ (2000) What is antibiotic resistance and how can we
measure it? Trends Microbiol 8:554–559
De Leenheer P, Cogan NG (2008) Failure of antibiotic treatment in microbial populations. J Math
Biol Dec 16 59:563–579
del Pozo JL, Patel R (2007) The challenge of treating biofilm-associated bacterial infections. Clin
Pharmacol Ther 82:204–209
del Pozo JL, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R (2009) The electricidal effect:
reduction of Staphylococcus and pseudomonas biofilms by prolonged exposure to low-inten-
sity electrical current. Antimicrob Agents Chemother 53:41–45
Dong Y, Zhao X, Domagala J, Drlica K (1999) Effect of fluoroquinolone concentration on
selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.
Antimicrob Agents Chemother 43:1756–1758
Dong Y, Zhao X, Kreiswirth CN, Drlica K (2000) Mutation prevention concentration as a measure
of antibiotic potency: studies with clinical isolates of Mycobacteriusm tuberculosis. Antimi-
crob Agents Chemother 44:2581–2584
Donlan RM, Costerton JW (2002) Biofilms: Survival mechanisms of clinically relevant micro-
organisms. Clin Microbiol Rev 15:167–193
Drlica K, Zhao X (2007) Mutation selection window hypothesis updated. Clin Infect Dis 44:681–688
Drlica K, Zhao X, Blondeau JM, Hesje C (2006) Low correlation between MIC and mutant
prevention concentration. Antimicrob Agents Chemother 50:403–404
Drusano GL (2007) Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis
45(Suppl 1):S89–S95
Drusano GL, Johnson DE, Rosen M, Standiford HC (1993) Pharmacodynamics of a fluoroquino-
lone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents
Chemother 37:483–490
Drusano GL, Liu W, Brown DL, Rice LB, Louie A (2009) Impact of short-course quinolone
therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis
199:219–226
Antimicrobial Drug Resistance 259